“Aim: The aim of this study is to analyze the impact of berberine on the two human epithelial ovarian carcinoma cell lines PF 00299804 OVCAR-3 and SKOV-3 in relation
to the potential usefulness of berberine in the treatment of epithelial ovarian cancer.
Methods: Under adherent culture conditions, the cell lines were treated with berberine and analyzed for changes in cell growth. The cell cycle duration and degree of apoptosis were evaluated by means of propidium iodide staining and Annexin V staining.
Results: After the berberine treatment, the two cell lines showed a dose-dependent reduction in the growth rate. In the cell cycle analysis, the OVCAR-3 and SKOV-3 cells showed an increased DNA content of 5% in the G2/M phase and 7% in the S phase, respectively. Additionally, the results confirm the cell cycle arrest by immunoblotting and the up-regulation of p27; however, in the apoptosis analysis, neither cell line showed an increase in apoptosis after the berberine Rapamycin order treatment.
Conclusion: Berberine treatment can inhibit proliferation through a cell cycle arrest in OVCAR-3 and SKOV-3 cells. Thus, berberine may be a novel anticancer drug
for the treatment of ovarian cancer.”
“BACK GROUND: For high-risk patients who do not achieve guideline-recommended LDL-C levels, more intensive treatment including statin-uptitration to higher doses or potency, as well as combination therapy may be considered. A better understanding of statin treatment patterns in real-world clinical practice may contribute to improved lipid-lowering management in these patients.
OBJECTIVE: We determined treatment pattern changes among patients with high risk of cardiovascular disease who were not at low-density lipoprotein cholesterol (LDL-C) goal on statin mTOR inhibitor monotherapy.
METHODS: Treatment pattern changes were evaluated among patients newly initiated on statins between January 1, 2006, and August 31, 2009, in the HealthCore Integrated Research Database. Rates and mean time to first and second treatment changes were examined in patients with claims for coronary heart disease (CHD), atherosclerotic vascular disease (AVD), and diabetes mellitus during 12 months before index, who were not at LDL-C <70 mg/dL
at their first-eligible LDL-C test (>= 4 weeks after index). Therapy change was assessed for 12 months after the LDL-C result.
RESULTS: Of 11,473 eligible subjects, 61.3% had diabetes, 26.6% had CHD and AVD, and 12.1% had CHD and AVD and diabetes. At index, patients were prescribed medium-potency levels of statins, including simvastatin (44.7%), atorvastatin (31.5%), and other statins (23.8%). Mean +/- SD LDL-C before statin initiation was 138 34 mg/dL, and at the first-eligible LDL-C result after index, it was 101 25 mg/dL. During follow-up, 7444 subjects (64.9%) experienced a first treatment change, with mean time to change of 93.8 +/- 92. days, whereas 4029 (36.1%) had no treatment change. Discontinuation of index therapy occurred in 46.